The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

Moderna Inc. entered the new year on the heels ... “(If I) tell you there’s this new biotech company…that has $2 billion of sales, two products approved, $9 billion in the bank, just filed ...

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

The meeting is a popular venue for dealmaking and discussions between pharma and biotech companies. Investors are eager to see more of Moderna’s pipeline become approved products. Moderna had ...

Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance.